951789-99-4

Upstream product

• 951789-98-3 (4Z)-(1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-4-[3'-hydroxypropylidene]-6-oxabicyclo[3.2.1]octan-7-one 
• 98-59-9 p-toluenesulfonyl chloride 
• 766529-94-6 (1R,3R,5R)-3-[(tert-butyldimethylsilyl)oxy]-1-hydroxy-6-oxa-bicyclo[3.2.1]octane-4,7-dione 
• 665-27-0 1,5-quinide 
• 163217-18-3 (1R,3R,4S,5R)-3-[(tert-butyldimethylsilyl)oxy]-1,4-dihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one 
• 77-95-2 D-(-)-quinic acid 
• 780781-83-1 (4Z)-(1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-6-oxa-4-[3-(methoxymethoxy)propylidene]bicyclo[3.2.1]octan-7-one 
• 766529-88-8 (1R,3R,5R)-1-acetoxy-3-[(tert-butyldimethylsilyl)oxy]-6-oxa-bicyclo[3.2.1]octane-4,7-dione 

Relevant academic research and scientific papers

19-Nor-Vitamin D Analogs with 1,2 or 3,2 Heterocyclic Ring

19-nor-vitamin D analogs having an additional heterocyclic ring connecting the 3β-oxygen and carbon-2 or the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit significant activity

Design, synthesis, and biological evaluation of a 1α,25-dihydroxy-19- norvitamin D3 analogue with a frozen A-ring conformation

To establish the conformation of vitamin D compounds responsible for biological activity, a 1α,25-dihydroxy-19-norvitamin D analogue 4 possessing a 1α-hydroxy group fixed in the axial orientation (β-chair form) was synthesized. The starting compounds were